Document:

Exhibit 10.1

 

Execution Copy

 

LEGACY
ASSETS SALE AGREEMENT

 

This
Agreement (this “Agreement”) is made as of January ____,
2018 by and among Immudyne, Inc., a Delaware corporation (the "Company"), and Mark McLaughlin (the “Purchaser”).

 

WHEREAS,
the Company desires to sell, and the Purchaser desires to purchase, substantially all of the assets and liabilities of the legacy
beta glucan business of the Company on the terms and subject to the conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the premises set forth herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

		1.	The
                                         Purchaser, through a to be formed entity (“Newco”), agrees to purchase the
                                         assets of the Company set forth in Exhibit A, for:

 

		a.	$650,000.00
(six hundred fifty thousand and no/100 dollars), payable on February 2, 2018 ( the “Closing Date”);
	 	 	 
		b.	$200,000.00
(two hundred thousand and no/100 dollars), payable in 120 days following the Closing Date; and
	 	 	 
		c.	the
waiver all rights to any severance payment in the stipulated amount of $150,000.00 (one hundred fifty thousand and no/100
dollars).

 

		2.	The
                                         assets are purchased AS IS, with no representations or warranties by the Company. The
                                         assets do not include $200,000.00 (two hundred thousand and no/100 dollars) in cash held
                                         by the Company as of the Closing Date and the rights to the INR Wellness brand. The Company
                                         also retains the nonexclusive right to use the name “Immudyne” for 60 days
                                         following the Closing Date.

 

		3.	Upon
                                         the sale of the assets, Newco will assume only the liabilities of the Company set forth
                                         in Exhibit A. The Company specifically retains the liability for the repayment of sums
                                         due Tricor Braun guaranteed by Purchaser, and the Company will insure that such sums
                                         are paid timely.

 

		4.	The
                                         Company will enter into a supply agreement with the Newco to purchase all of the yeast
                                         beta glucan for the INR Wellness products at a price of $499.00 for one year from the
                                         Closing Date.

 

		5.	Upon
                                         the Closing Date, the Purchaser will resign his positions as an executive officer and
                                         director of the Company, and the Purchaser’s employment agreement is in all aspects
                                         terminated, and neither party shall have any ongoing obligations thereunder except as
                                         are set forth in this Agreement.

 

     

     

    

 

		6.	Upon
                                         the Closing Date, Justin Schreiber agrees to become the President and CEO of the Company
                                         for at least a two year term.

 

		7.	Upon
                                         the Closing Date, Stefan Galluppi will resign his position as a director of the Company.

 

		8.	For
                                         so long as Purchaser owns or controls over 9.9% of the outstanding shares of the Company,
                                         and subject to the Bylaws of the Company, Purchaser will have the right to appoint one
                                         director of the Company. Upon the Closing Date, Anthony Bruzzese M.D. shall be Purchaser’s
                                         designated director. In the event that Anthony Bruzzese M.D. ceases to be a director,
                                         the Company and the undersigned directors agree to support and vote in favor of the replacement
                                         director designated by Purchaser.

 

		9.	The
                                         Company will issue a press release in substantially the form set forth in Ex. B. For
                                         a period of eighteen months from the closing date, the Company, its directors and the
                                         Purchaser agree not to make any oral or written statements that defame, disparage or
                                         in any way criticize the business reputation, practice or conduct of the Company, the
                                         Purchaser, their employees, directors and officers.

 

		10.	Upon
                                         the Closing Date, the Purchaser agrees to forgo and waive any rights to any unvested
                                         options in any employment, consulting or director’s agreements.

 

		11.	The
                                         Company agrees to effectuate any future exercise of options and to promptly provide to
                                         the Purchaser the shares of the Company’s stock pursuant to the option exercise
                                         (subject to any securities laws). The vested options and the exercise terms are set forth
                                         in Ex. C.

 

		12.	The
                                         Purchaser agrees to abide by all securities laws in the sale or transfer of his shares
                                         of the Company’s stock. Except for any transactions pursuant to Section 13 below,
                                         Purchaser further agrees that he will not, directly or indirectly, during a period of
                                         one year from the Closing Date, (i) offer, sell, contract to sell, grant or sell
                                         any option, right or warrant for the purchase of, pledge, hypothecate, assign, lend or
                                         otherwise transfer or dispose (collectively, a “Sale”) of any of the shares
                                         an amount greater than 250,000 shares in any 30 day period (the “Volume Restriction”);
                                         (ii) enter into any swap or any other arrangement or transaction that transfers
                                         to another, in whole or in part, any of the economic characteristics of ownership of
                                         his shares, whether any such swap or transaction is to be settled by delivery of such
                                         shares, in cash or otherwise in excess of the Volume Restriction; or (iii) engage
                                         in any short selling of the Shares. Notwithstanding the above restrictions, the Purchaser
                                         may transfer options or shares to any individual or entity so long as that individual
                                         or entity agrees in writing to comply with the Volume Restriction. Subject only to the
                                         above restrictions, the Company agrees to promptly effectuate the future transfer by
                                         the Purchaser of his and/or his family’s shares of the Company’s stock.

 

    	 	-2-	 

     

    

 

		13.	If
                                         the Company shall determine to register for its own account or the account of others
                                         under the Securities Act of 1933 any of its equity securities, the Company shall include
                                         in such registration statement all of the Shares and options owned by Purchaser. Notwithstanding
                                         the foregoing, in the event that any registration shall be in whole or in part an underwritten
                                         offering, the number of registrable securities to be included in such an underwriting
                                         may be reduced (pro rata among the Purchaser and the holders of the other registrable
                                         securities contemplated being included in such registrations based on the number of registrable
                                         securities requested to be registered by each of them) if and to the extent that the
                                         managing underwriter shall be of the good faith opinion (expressed in writing) that such
                                         inclusion would reduce the number of registrable securities to be offered by the Company
                                         or otherwise adversely affect such offering. Nothing herein shall be construed so as
                                         to require the Company, in connection with any proposed offering, to engage the services
                                         of an underwriter, as, for example, if the Company shall file a registration statement
                                         under Rule 415 of the Securities Act without the services or engagement of any underwriter.
                                         This “piggy-back” registration right shall not apply to an offering of equity
                                         securities registered on Form S-4 or S-8 (or their then equivalent forms) relating to
                                         securities to be issued solely in connection with an acquisition of any entity or business
                                         or securities issuable in connection with a stock option or other employee benefit plan.

 

		14.	The
                                         Company agrees to indemnify and hold harmless the Purchaser from any and all losses,
                                         liabilities, obligations, claims, contingencies, damages, costs and expenses, including
                                         all judgments, fines, amounts paid in settlements, court costs and reasonable attorneys’
                                         fees and costs of investigation that the Purchaser may suffer or incur as a result of
                                         or relating to or arising out of his actions or inactions as a director or officer of
                                         the Company.

 

		15.	EXCEPT
                                         FOR THE RIGHTS IN PARAGRAPH 14 ABOVE, THE PURCHASER HEREBY RELEASES AND FOREVER DISCHARGES
                                         THE COMPANY, AND EACH OF ITS SUCCESSORS, ASSIGNS, DIRECTORS, MANAGERS, OFFICERS, SHAREHOLDERS,
                                         MEMBERS, SUBSIDIARIES, REPRESENTATIVES, EMPLOYEES, AGENTS AND LEGAL COUNSEL, AND THEIR
                                         RESPECTIVE AFFILIATES, SUCCESSORS, ASSIGNS, HEIRS AND PERSONAL REPRESENTATIVES OF EACH
                                         OF THE FOREGOING (COLLECTIVELY, THE “COMPANY AFFILIATES”),
                                         SEVERALLY AND JOINTLY, FROM ANY AND ALL CLAIMS, LIABILITIES, COSTS AND DAMAGES OF ANY
                                         NATURE WHATSOEVER, KNOWN AND UNKNOWN, ARISING IN WHOLE OR IN PART AT ANY TIME PRIOR TO
                                         THE EXECUTION OF THIS AGREEMENT IN CONNECTION WITH HIS POSITION AS AN OFFICER OR DIRECTOR
                                         OF THE COMPANY, INCLUDING ANY AND ALL STATUTORY AND COMMON LAW CAUSES OF ACTION WHICH
                                         THE PURCHASER NOW HAS OR MAY BELIEVE HE HAS AGAINST THE COMPANY OR ANY COMPANY AFFILIATE
                                         ON OR AT ANY TIME PRIOR TO THE DATE OF THIS AGREEMENT.

 

    	 	-3-	 

     

    

 

		16.	THE
                                         COMPANY HEREBY RELEASES AND FOREVER DISCHARGES THE PURCHASER AND EACH OF HIS SUCCESSORS,
                                         ASSIGNS, REPRESENTATIVES, FAMILY MEMBERS, AGENTS AND LEGAL COUNSEL, AND THEIR RESPECTIVE
                                         AFFILIATES, SUCCESSORS, ASSIGNS, HEIRS AND PERSONAL REPRESENTATIVES OF EACH OF THE FOREGOING
                                         (COLLECTIVELY, THE “PURCHASER’S AFFILIATES”), SEVERALLY
                                         AND JOINTLY, FROM ANY AND ALL CLAIMS, LIABILITIES, COSTS AND DAMAGES OF ANY NATURE WHATSOEVER,
                                         KNOWN AND UNKNOWN, ARISING IN WHOLE OR IN PART AT ANY TIME PRIOR TO THE EXECUTION OF
                                         THIS AGREEMENT IN CONNECTION WITH HIS POSITION AS AN OFFICER OR DIRECTOR OF THE COMPANY,
                                         INCLUDING ANY AND ALL STATUTORY AND COMMON LAW CAUSES OF ACTION WHICH THE COMPANY OR
                                         THE COMPANY AFFILIATES NOW HAVE OR MAY BELIEVE THEY HAVE AGAINST THE PURCHASER AND THE
                                         PURCHASER’S AFFILIATES ON OR AT ANY TIME PRIOR TO THE DATE OF THIS AGREEMENT.

 

		17.	Miscellaneous.

 

(a)       Further
Assurances.  If at any time after the date hereof any further action is necessary to carry out the purposes of this Agreement,
each of the parties will take such further action (including the execution and delivery of such further instruments and documents)
as the other party reasonably may request.

 

(b)       Successors
and Assigns. This Agreement shall be binding upon and will inure to the benefit of the parties hereto and their respective
heirs, legal representatives, successors and assigns.

 

(c)       Entire
Agreement. This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof.

 

(d)       Amendment.
This Agreement may not be amended except by an instrument signed by the parties hereto.

 

(e)       Notices.
All notices, requests, demands, claims, and other communications hereunder shall be in writing. Any notice, request, demand, claim,
or other communication hereunder shall be deemed duly given three (3) days after sent by registered or certified mail, return
receipt requested, postage prepaid, and addressed to the intended recipient at the address set forth on the signature page hereto.
Any party may send any notice, request, demand, claim, or other communication hereunder to the intended recipient at the address
set forth on the signature page hereto using any other means (including personal delivery, expedited courier, messenger service,
telecopy, telex, ordinary mail, or electronic mail), but no such notice, request, demand, claim, or other communication shall
be deemed to have been duly given unless and until it is actually delivered to (or received by) the other party at that party’s
address set forth on the signature page hereto. Any party may change the address to which notices, requests, demands, claims,
and other communications hereunder are to be delivered by giving the other parties notice in the manner herein set forth.

 

    	 	-4-	 

     

    

 

(f)       Headings.
Section headings in this Agreement are included for convenience of reference only and shall not constitute a part of this Agreement
for any other purpose.

 

(g)       Governing
Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Texas, without giving
effect to principles of conflict of laws.

 

(h)       Mediation.In
the event of any dispute arising under or pursuant to this Agreement, the Parties agree to attempt to resolve the dispute in a
commercially reasonable fashion before instituting any arbitration or litigation (with the exception of emergency injunctive relief
as set forth in Paragraph 8). If the Parties are unable to resolve the dispute within thirty (30) days, then the Parties agree
to mediate the dispute with a mutually agreed upon mediator in Houston, Texas. If the Parties cannot agree upon a mediator within
ten (10) days after either party shall first request commencement of mediation, each party will select a mediator within five
(5) days thereof, and those mediators shall select the mediator to be used. The mediation shall be scheduled within thirty (30)
days following the selection of the mediator. If the mediation does not resolve the dispute, then Paragraph 17(i) shall apply.
The Parties further agree that any applicable statute of limitations will be tolled for the period of time from the date mediation
is requested until 14 days following the mediation.

 

(i)       Jurisdiction
and Venue.The sole and exclusive jurisdiction and venue for any action or proceeding arising from or relating to this
Agreement shall be the federal and state courts located in Harris County, Texas, and all parties hereto consent to the jurisdiction
of such courts. If any action or proceeding is brought by any party arising from or relating to this Agreement or in any appeal
therefrom, it is agreed that the prevailing party shall be entitled to reasonable attorneys’ fees to be fixed by the trial
court, and/or appellate court if such party substantially prevails on all the issues in dispute.

 

(j)       Counterparts.
This Agreement may be executed in counterparts, each of which shall be an original and all of which together shall constitute
but one and the same agreement.

 

[Remainder
of Page Intentionally Left Blank]

 

    	 	-5-	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.

 

	 	IMMUDYNE, INC.
	 	 	 
	 	By:	
	 	 	Robert Kalkstein
	 	 	Chief Financial Officer
	 	 	By Special Authorization of the Board

 

	 	 	Address:
	 	 	 
	 	 	 
	 	 	JUSTIN SCHREIBER
	 	 	 
	 	 	Address:
	 	 	 
	 	 	 
	 	 	RYAN ALDRIDGE
	 	 	 
	 	 	Address:
	 	 	 
	 	 	 
	 	 	MARK MCLAUGHLIN
	 	 	 
	 	 	Address:
	 	 	 
	 	 	 
	 	 	JOHN R. STRAWN JR.
	 	 	 
	 	 	Address:
	 	 	 
	 	 	 
	 	 	JOSEPH DITROLIO M.D.
	 	 	 
	 	 	Address:
	 	 	 
	 	 	 
	 	 	ANTHONY BRUZZESE M.D.
	 	 	 
	 	 	Address:
	 	 	 
	 	 	 
	 	 	MICHAEL BORENSTEIN M.D.
	 	 	 
	 	 	Address:
	 	 	 
	 	 	 
	 	 	STEFAN GALLUPPI
	 	 	 
	 	 	Address:

 

    	 	-6-	 

     

    

 

EXHIBIT
A

 

ASSETS:

 

		1.	All
                                         equipment, tools, computers, fixtures, supplies, materials, inventory and other property
                                         contained in the facility located at 7453 Empire Drive, Suite 300, Florence, KY 41042;
	 	 	 
		2.	All
                                         equipment, tools, computers, fixtures, supplies, materials, inventory and other property
                                         used by Daniel Sese and/or Caitlin Arnest in connection with the facility located at
                                         7453 Empire Drive, Suite 300, Florence, KY 41042;
	 	 	 
		3.	All
                                         equipment, tools, computers, fixtures, supplies, materials, inventory and other property
                                         contained in the facility located at 50 Spring Meadow Road, Mount Kisco, NY 10549;
	 	 	 
		4.	All
                                         equipment, tools, computers, fixtures, supplies, materials, inventory and other property
                                         contained in the facility located at 423 N. Theard St., Covington, LA 70433;
	 	 	 
		5.	The
                                         membrane system currently under construction by Membrane Specialists LLC;
	 	 	 
		6.	All
                                         accounts receivables;
	 	 	 
		7.	All
                                         intellectual property, processes, formulas, studies, data, flowcharts, know-how, patents,
                                         patent applications, trademarks, and other information related to the beta glucan business
                                         (the Company agrees to execute assignments of any valid trademarks, patents and patent
                                         applications);
	 	 	 
		8.	The
                                         rights to name “Immudyne”, and the websites used by the beta glucan business
                                         (Immudyne.com and yeastbetaglucan.com);
	 	 	 
		9.	All
                                         accounts in the Fifth Third Bank (after the transfer of the $200,000.00 referenced in
                                         Section 2 above).

 

LIABILITIES:

 

		1.	All
                                         leases and/or payments for the facility and the equipment, tools, computers, fixtures,
                                         supplies, materials, inventory and other property contained in the facility located at
                                         7453 Empire Drive, Suite 300, Florence, KY 41042;
	 	 	 
		2.	All
                                         leases and/or payments for the equipment, tools, computers, fixtures, supplies, materials,
                                         inventory and other property used by Daniel Sese and/or Caitlin Arnest in connection
                                         with the facility located at 7453 Empire Drive, Suite 300, Florence, KY 41042;
	 	 	 
		3.	All
                                         leases and/or payments for the equipment, tools, computers, fixtures, supplies, materials,
                                         inventory and other property contained in the facility located at 50 Spring Meadow Road,
                                         Mount Kisco, NY 10549;
	 	 	 
		4.	All
                                         leases and/or payments for the equipment, tools, computers, fixtures, supplies, materials,
                                         inventory and other property contained in the facility located at 423 N. Theard St.,
                                         Covington, LA 70433;
	 	 	 
		5.	All
                                         payments for the membrane system currently under construction by Membrane Specialists
                                         LLC;
	 	 	 
		6.	All
                                         outstanding payments for any intellectual property, processes, formulas, studies, data,
                                         flowcharts, know-how, patents, patent applications, trademarks, and other information
                                         related to the beta glucan business;
	 	 	 
		7.	All
                                         payments due to Daniel Sese, Caitlin Arnest, Bruni McLaughlin, and V-Labs for services
                                         incurred following the Closing Date;

 

    	 	-7-	 

     

    

 

EXHIBIT
B

 

ImmuDyne Announces Management Changes & Sale of Legacy
Manufacturing Business 

 

New York, N.Y., January 30, 2018 (GLOBE NEWSWIRE) -- ImmuDyne,
Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and online marketing of OTC
health and wellness products addressing large unmet needs, today announces the sale of its Yeast Beta Glucan manufacturing business,
the resignation of Mark McLaughlin as President & CEO, and the appointment of Justin Schreiber as the Company’s President
& CEO.

 

Sale of Yeast Beta Glucan Manufacturing Business 

 

As Immudyne has successfully pivoted to direct-to-consumer marketing
over the last two years, and this has become the Company’s primary source of revenue, the Company believes it to be in the
best interest of shareholders to divest of non-core assets, such as our legacy beta glucan manufacturing business. Immudyne entered
into a definitive sale agreement with a third party that will acquire 100% of the assets and liabilities of this business unit.
Immudyne will receive net cash proceeds of approximately $850,000 from this transaction.

 

“The majority of Immudyne’s revenue growth over
the past 24 months has come from our online direct to consumer marketing business,” stated Justin Schreiber, Immudyne’s
incoming President & CEO. “This business is now profitable and growing with a robust pipeline of products that will be
launching in 2018. Our decision to monetize our non-core manufacturing business will drastically shrink our overall corporate burn
rate, increase profitability, and provide Immudyne with non-dilutive cash that we believe can be used to scale our business.”

 

Resignation of Mark McLaughlin as President, CEO & Director

 

In conjunction, Mark McLaughlin has
resigned from his role as President & CEO of Immudyne and from the Company’s board of directors. Mr. McLaughlin was one
of several individuals that agreed to purchase the manufacturing business from Immudyne, and he will continue to operate the business
as a private company. The new private company will continue to supply yeast beta glucan to the Company on favorable terms.

 

“It’s been my pleasure
to serve as President & CEO of Immudyne for the past 5 years,” stated Mark McLaughlin. “Immudyne’s direction
has changed considerably since the acquisition of our online marketing division over 2 years ago, and I agree with the board of
directors’ decision to divest of our legacy manufacturing business and refocus the company’s resources on what has
become our core business. I look forward to following the success of the Company.”

 

Concurrent with his resignation, Mr.
McLaughlin has agreed to sell 2,800,000 shares of Immudyne common stock to a third-party affiliated with Justin Schreiber and Stefan
Galluppi, Immudyne’s CEO and CTO.

 

Appointment of Justin Schreiber
as President & CEO of Immudyne, Inc.

 

Justin Schreiber has been appointed
Immudyne’s President & Chief Executive Officer. He is also a member of Immudyne’s board of directors. Mr. Schreiber
and his partner Stefan Galluppi founded and provided the bulk of the financing for Immudyne’s direct to consumer marketing
business. Mr. Schreiber is the founder of JLS Ventures, LLC, a San Juan based venture investment and advisory firm that specializes
in emerging growth publicly traded healthcare and technology companies. He has a deep background in small cap markets, private
equity, trading, and online marketing. Mr. Galluppi is an entrepreneur with an accomplished track record in technology and direct
response marketing.

 

“I am very excited about Immudyne’s
growth prospects in the coming years,” stated Mr. Schreiber. We’ve invested heavily over the past 2 years to build
what I believe is one of the best online marketing teams in the world. We intend to aggressively grow revenue, launch a variety
of new products, and uplist the company to a national stock exchange in 2018.”

 

Immudyne plans to provide additional
updates on new products and sales traction later in the first quarter.

 

    	 	-8-	 

     

    

 

About lmmudyne, Inc.

 

lmmudyne, Inc. (the "Company")
is a health and wellness company that develops, manufactures, and markets innovative consumer products in the health and wellness
sector. Immudyne’s business model is highly scalable and extremely capital efficient. The Company relies on the world’s
largest internet and social media platforms to directly market its portfolio of products to consumers around the world. Immudyne’s
lead product is Shapiro MD, a hair care aid developed by distinguished dermatologists and supported by strong science. Additionally,
Immudyne owns and markets INR Wellness, an immune support supplement. Immudyne intends to launch several additional health and
wellness products in 2018. Additional information can be found on the web at www.immudyne.com.

 

Forward-Looking Statements

 

Cautionary language regarding Forward-Looking
Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made pursuant to the Safe Harbor Provisions
of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect
to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could,"
"estimates," "expects," "intends," "may," "projects," "plans," 
"targets" and other similar language and are considered forward-looking statements. These statements are based on management's
current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and
uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

 

Investor Relations Contact:

 

Bernard Girma

bfgirma@immudyne.com

+1-949-215-7754

 

    	 	-9-	 

     

    

 

EXHIBIT
C

 

		1.	1,800,000
                                         (one million eight hundred thousand) shares of Common Stock of the Company, such shares
                                         purchasable at an exercise price of $0.20 (twenty cents) per share until October 11,
                                         2022.

 

		2.	500,000
                                         (five hundred thousand) shares of Common Stock of the Company, such shares purchasable
                                         at an exercise price of $0.40 (forty cents) per share until October 11, 2022.

 

		3.	500,000
                                         (five hundred thousand) shares of Common Stock of the Company, such shares purchasable
                                         at an exercise price of $0.40 (forty cents) per share until January 1, 2027.

 

		4.	250,000
                                         (two hundred fifty thousand) shares of Common Stock of the Company, such shares purchasable
                                         at an exercise price of $0.35 (thirty-five cents) per share until June 30, 2027.

 

If
the Company is prevented from issuing any of options or the stock due to pending litigation, or for any other reason, then the
expiration date(s) will commence (or recommence, if applicable) when the Company’s options or the stock relating thereto
are no longer subject to current litigation, or any other contingency prohibiting the Company from issuing said options or stock.
All shares resulting from the exercise of options shall have the same rights as all other shares of the Company's capital stock.
Further, if the Company should split its stock prior to the granting or exercise of said options, then the options shall be split
in a similar manner and the exercise price shall be adjusted to prevent any dilution or increase in Executive’s interest
in the Company's stock once the options are granted or exercised. Executive or his Estate will have the right to assign all his
options, and the rights to his options. Executive’s options and the rights to his future options do not terminate with his
death. The options may be exercised by his heirs and his assigns and their heirs.

 

If
all or any portion of the options are exercised at a time when there is an effective registration statement to cover the issuance
or resale of the option shares, the shares issued pursuant to any such exercise shall be issued free of all legends. If at any
time following the date hereof the registration statement (or any subsequent registration statement registering the sale or resale
of the option shares) is not effective or is not otherwise available for the sale or resale of the option shares, the Company
shall immediately notify the holders of the options in writing that such registration statement is not then effective and thereafter
shall promptly notify such holders when the registration statement is effective again and available for the sale or resale of
the option shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any
purchaser to sell, any of the option shares in compliance with applicable federal and state securities laws). The Company shall
use best efforts to file a registration statement registering the issuance or resale of the option shares during the term of the
options.

 

 

-10-Exhibit
10.2

 

FIRST
AMENDMENT TO LEGACY ASSETS SALE AGREEMENT

 

THIS
FIRST AMENDMENT TO LEGACY ASSETS SALE AGREEMENT ( “First Amendment”) is made as of February 7, 2018 (the “Effective
Date”) by and among Immudyne, Inc. a Delaware corporation (“the Company”) and Mark McLaughlin (the “Purchaser”),
collectively herein referenced as “the Parties”.

 

WHEREAS,
the Parties entered into the Legacy Assets Sale Agreement dated January 26, 2018, and now the Parties desire to enter into this
First Amendment to the Legacy Assets Sale Agreement for the mutual benefit of the Parties;

 

NOW
THEREFORE, for good and valuable consideration, the terms and conditions of Sections 1 and 2 of the Legacy Assets Sale Agreement
are amended and are now agreed to be as follows (each in their entirety):

 

		1.	The
                                         Purchaser, through a to be formed entity (“Newco”), agrees to purchase the
                                         assets of the Company set forth in Exhibit A, for:

 

	 	a.
    	2,000,000
    (two million) shares of Immudyne, Inc. (valued at $0.23/share or $460,000.00), payable on February 12, 2018 (the “Closing
    Date”);
	 	 	 
	 	b.	$190,000
    (one hundred ninety thousand and no/100 dollars), payable on the Closing Date;
	 	 	 
	 	c.	$200,000.00
    (two hundred thousand and no/100 dollars), payable in 120 days following the Closing Date; and
	 	 	 
	 	d.
    	the
    waiver all rights to any severance payment in the stipulated amount of  $150,000.00 (one hundred fifty thousand and no/100
    dollars).

 

	 	2.	The assets are purchased AS IS, with no representations
or warranties by the Company. The
assets do not include $194,682.78 (one hundred ninety four thousand six hundred eighty two and 78/100 dollars) in cash held
by the Company as of the Closing Date and the rights to the INR Wellness brand. The Company also retains the nonexclusive
right to use the name “Immudyne” for 60 days following the Closing Date.

 

All
other terms of Legacy Assets Sale Agreement dated January 26, 2018 remain in full force and effect.

 

This
First Amendment may be executed in multiple counterparts, each of which shall be deemed an original, and all such counterparts
shall together constitute one and the same document. This First Amendment may be executed via facsimile or electronic signature,
and each such facsimile copy, electronic signature or counterpart shall be deemed an original.

 

The
parties represent and warrant that, on the date first written above, they are authorized to enter into this First Amendment in
its entirety and duly bind their respective principals by their signatures below.

 

     

     

    

 

EXECUTED
as of the date first written above.

 

	 	immudyne,
    INC.
	 	 	 
	 	By:	    
	 	 	Robert
    Kalkstein
	 	 	Chief
    Financial Officer
	 	 	By
    Special Authorization of the Board
	 	 	 
	 	 
	 	JUSTIN
    SCHREIBER
	 	 	 
	 	Address:
	 	 	 
	 	 
	 	RYAN
    ALDRIDGE
	 	 	 
	 	Address:
	 	 	 
	 	 
	 	MARK
    MCLAUGHLIN
	 	 	 
	 	Address:
	 	 	 
	 	 
	 	JOHN
    R. STRAWN JR.
	 	 	 
	 	Address:
	 	 	 
	 	 
	 	JOSEPH
    DITROLIO M.D.
	 	 
	 	Address:
	 	 	 
	 	 
	 	ANTHONY
    BRUZZESE M.D.
	 	 	 
	 	Address:
	 	 	 
	 	 
	 	MICHAEL
    BORENSTEIN M.D.
	 	 	 
	 	Address:
	 	 	 
	 	 
	 	STEFAN
    GALLUPPI
	 	 	 
	 	Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]